Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇
about
Biosynthesis of α-pyronesCrystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 ProteaseDesign and Synthesis of HIV-1 Protease Inhibitors Incorporating Oxazolidinones as P2/P2‘ Ligands in Pseudosymmetric Dipeptide IsosteresHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsEvaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug ResistanceStructure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating PhenyloxazolidinonesP2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran MoietyPrediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Novel compounds in preclinical/early clinical development for the treatment of HIV infections.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesRole of tipranavir in treatment of patients with multidrug-resistant HIVInteraction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.Tipranavir: a new protease inhibitor for the pediatric population.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations.New anti-HIV agents and targets.Early factors in successful anti-HIV treatment.Molecular Basis for Drug Resistance in HIV-1 ProteaseProtocol for rational design of covalently interacting inhibitors.Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.Emerging anti-HIV drugs.Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.Tipranavir: a protease inhibitor for HIV salvage therapy.Tipranavir: a new option for the treatment of drug-resistant HIV infection.Facile N-arylation of amines and sulfonamides and o-arylation of phenols and arenecarboxylic acidsTesting the substrate-envelope hypothesis with designed pairs of compounds.5‑bromo‑3‑(3‑hydroxyprop‑1‑ynyl)‑2H‑pyran‑2‑one induces apoptosis in T24 human bladder cancer cells through mitochondria-dependent signaling pathways.Looking at the proteases from a simple perspective.Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.Tipranavir in the protease inhibitors arena.Human Immunodeficiency Virus Gag and protease: partners in resistance.Process Chemistry in Antiviral Research.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses.Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.
P2860
Q26747290-CB87B34B-B922-4E9D-8AE3-D9E84AF8187EQ27646453-5B972EDC-835D-4101-9ACF-29F84DDD8E4EQ27647177-EE8AEFAB-E9B2-4648-9359-C528CF1E80BFQ27650325-4319DFF8-F7F2-496A-92DC-FA317E748003Q27660267-4121682B-ECFF-4D2E-974F-0DD137CDA387Q27665164-BC1D586F-6E06-4170-948A-1E0C3FC84DC8Q27679177-DD25DAAF-3BAB-4669-90DD-EAAAAF9CCFF9Q33814096-C479215B-7B83-49AC-81D4-629B0B46FF4FQ33906239-A3381861-EFC8-4B96-B30F-0AFDDC0D0AD8Q33966254-F41762DD-6F24-4F0A-BBC2-828197FA9B5BQ34102058-F70DE05D-044B-439C-A0A1-FDA371487487Q34187649-32387A41-B9CD-49D8-B7E3-8FCB9EACFA72Q34228277-E2F4F7F8-0A71-4D08-B14C-E66D0309B0FCQ34601313-C3705AD1-2008-4CB0-B8EA-62B8B4ED0F43Q34633457-42BEE890-2ECF-4CE1-B171-9EB539521B48Q34674166-2EBE92FB-72DF-4AEA-8C2A-70A2A901F222Q34906937-F4473791-E6B5-42AD-8F60-04ADB16FF0E0Q34944447-910C6DA5-8C53-49AA-A966-7B8233FD08C5Q35207282-D157B7F4-D4E2-4345-A06B-AAEE606FADBEQ35260370-09C5A6E1-9E59-4389-BC27-FC83D0DA3793Q35273893-88D6BACC-5CEE-4009-81EE-6EEF52378C59Q35570956-96175F80-366F-4754-A414-45F98ACDCCC2Q35935885-DB6E4B6A-90E4-4E3E-9983-39ADEF3C54D4Q36150601-6DC0B071-9D3A-4504-A37D-727C6346E692Q36349653-8BC9679F-9969-4290-9BBF-90F2345BD8E7Q36482890-A3355305-FFB4-4875-AE9E-37CB74FDEEFBQ36513619-6C376331-2BB2-445E-80D2-34F7F0E6F431Q36916096-4D46ECEA-5B3C-45D0-933B-A3D2E27B6F64Q37063610-F5F3B59A-5EA1-40BB-8710-D88E9578D689Q37323254-C59980E1-A8E2-482A-B86B-DC7FF96C8CE2Q37707686-6FCD8E71-5CC4-4AA8-8817-D00DCA557DF8Q37848282-05A45B38-9DBA-4D7E-AC09-2C34AE1DF488Q37909409-8C970AD4-1B5E-4889-8DBD-7E9A1606AA01Q37963591-BD7012BD-DCFF-483D-A579-23FC6045EDF9Q38032330-5BC7C835-3F9E-44C4-8C71-2B3A602EA6EFQ38997200-B8249A1A-7374-407C-ADCC-4541C244721BQ40055204-5AF34C78-7537-4C34-AED7-7DBEC8E091CEQ42003165-BC6620CB-5823-4B0A-9E70-2E65B5CACD9DQ45245263-B22A286B-E7D7-4554-9BA8-063644B51269Q46990276-72B7F14B-45E6-4C60-A788-E144F79D3EB2
P2860
Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇
@ast
Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇
@en
type
label
Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇
@ast
Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇
@en
prefLabel
Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇
@ast
Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇
@en
P2093
P3181
P356
P1476
Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇
@en
P2093
Eric P. Seest
Harvey I. Skulnick
Janet C. Lynn
Joseph W. Strohbach
Keith D. Watenpaugh
Kong-Teck Chong
Lester A. Dolak
Miao-Miao Horng
Michael J. Bohanon
Musiri N. Janakiraman
P304
P3181
P356
10.1021/JM9802158
P407
P577
1998-08-01T00:00:00Z